Login
Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

krystalbio.com

What Do They Do?

Sells VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa, and develops genetic medicines for rare diseases affecting the skin, lungs and eyes.

How Do They Make Money?

Customers pay for VYJUVEK when it is delivered to them. The company sells it to specialty pharmacy providers, hospitals and specialty distributors.

FY2025 revenue

Who Are Their Customers?

Specialty pharmacies, hospitals and specialty distributors buy VYJUVEK directly from the company; pharmacies prepare it for healthcare professionals, while hospitals and distributors supply hospital use.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 87% from one customer

Do Revenues Turn Into Profits?

Yes. It kept 53 cents of every revenue dollar as net income in FY2025 and turned 49 cents into free cash flow.

Operating income, FY2025
41% of revenue
▲ +145% vs FY2024 ($65.7M, 23%)
Net income, FY2025
53% of revenue
▲ +130% vs FY2024 ($89.2M, 31%)
Free cash flow, FY2025
49% of revenue
▲ +59% vs FY2024 ($119.2M, 41%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −21%
vs $79.4M in Q3 FY2025
  • Jul 21, 2026 A single KB801 patient showed closure of a corneal defect The observation came from a discontinued study and does not establish the therapy’s safety or effectiveness.

Who Do They Compete With?

Competes with Abeona Therapeutics, Castle Creek Biosciences, BridgeBio Pharma, Chiesi Farmaceutici, RHEACELL, Vertex Pharmaceuticals, ReCode Therapeutics, Spirovant Sciences, 4D Molecular Therapeutics, CSL, Takeda Pharmaceutical, Grifols, Kamada, Sanofi, Peak Bio, Mereo BioPharma Group, Wave Life Sciences, Beam Therapeutics, Dompé farmaceutici, and Merck &

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support